The number of people living with heart failure (HF) worldwide more than doubled between 1990 and 2023, reaching an estimated ...

Washington, DC, clinicians shared how order sets, pharmacist-led dosing, and better handoffs can close iron deficiency gaps ...

Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection. Invivyd plans to seek accelerated approval for VYD2311 based ...

The conference, held in New Orleans, Louisiana, by the American Academy of Ophthalmology, will offer 3 full days of content ...

Patients with early-onset, BRAF V600E–mutated metastatic colorectal cancer should receive combination therapy as soon as ...

The FDA approved tucatinib (Tukysa; Pfizer) in combination with trastuzumab and pertuzumab for the maintenance treatment of ...

Stutsky explains why shifting therapy perceptions had more pharmacist touchpoints and longer time on therapy among patients with ATTR-CM.

Population Health, Equity & Outcomes is a quarterly publication dedicated to providing a platform for the exchange of research, policy analysis, and insights that aim to improve health outcomes and ...

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press. Insurance Business cited the AJMC study as evidence for its central argument: a larger PBM rebate ...

Michael Mina, MD, PhD, explains which adverse events drove VYD2311's edge vs an mRNA COVID-19 vaccine and who may benefit most.

Esperion launched a nationwide awareness campaign for bumetanide nasal spray (Enbumyst), a short-term intranasal loop ...

AJMC: Despite ATTR-CM being a progressive disease, 74% of patients reported no change in perception. Is that reassuring from ...